

Attorney Docket No.: 6151.200-US
Application Serial No.: 09/732,398
Filed: December 7, 2000
Inventors: Gerhard Jorgen Darr
Attorney Docket No.: 6151.200-US

RECEIVED
CENTRAL FAX CENTER
FEB 09 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gerhard Jørgen Darr

Application No.: 09/732,398

Group Art Unit: 1731

Filed: December 7, 2000

Examiner: Catherine Simone

Confirmation No: 9875

For: Markings on Transparent Plastic

**PETITION FOR WITHDRAWAL OF A HOLDING OF
ABANDONMENT UNDER 37 CFR 1.181(a)**

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants' respectfully petition the USPTO to withdraw its holding of abandonment of the above identified application. Applicant's never received the final rejection mailed by the USPTO on Jan 28 2004 because the USPTO mailed it to an old, out-of-date address. Applicants respectfully submit this abandonment is the result of USPTO error. Applicants did not receive the aforementioned correspondence because the USPTO used an incorrect applicant address for the mailing.

Applicant's attorneys properly changed their correspondence address and the USPTO noted receipt of such a change of address in September 2002. Notwithstanding this fact, the USPTO mailed the final rejection dated Jan 28, 2004, to the old, out-of-date address. As a result, Applicants were not aware that an office action had been mailed.

Applicants have attached herewith a copy of the Request for Customer Number Data Change transmitted September 11, 2002, evidencing Novo Nordisk Pharmaceutical Company's first of many requests for a change of correspondence address. Also attached is a copy of the USPTO Notice of Customer Number Record Change, mailed September 12, 2002,

BEST AVAILABLE COPY


Attorney Docket No.: 6151.200-US
Application Serial No.: 09/732,398
Filed: December 7, 2000
Inventors: Gerhard Jorgen Darr
acknowledging the acceptance of the request to change information associated with Customer
Number 23650.

Applicants respectfully request the withdrawal of the abandonment by the USPTO
without requiring Applicants to file a Petition to Revoke.

Please charge the required fee, estimated to be \$130, with this petition and credit
any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please
charge any additional fees, should they be required, to Deposit Account No. 14-1447. A
duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 12, 2004



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

CUSTOMER NUMBER
23650
PATENT TRADEMARK OFFICE